Bibliographic Details
| Title: |
One-year outcomes in cardiogenic shock triggered by supraventricular tachycardia: an analysis of the FRENSHOCK multicenter prospective registry |
| Authors: |
Miloud Cherbi, Eric Bonnefoy, Nicolas Lamblin, Edouard Gerbaud, Laurent Bonello, François Roubille, Bruno Levy, Sebastien Champion, Pascal Lim, Francis Schneider, Meyer Elbaz, Hadi Khachab, Jeremy Bourenne, Marie-France Seronde, Guillaume Schurtz, Brahim Harbaoui, Gerald Vanzetto, Nicolas Combaret, Vincent Labbe, Benjamin Marchandot, Benoit Lattuca, Caroline Biendel-Picquet, Guillaume Leurent, Etienne Puymirat, Philippe Maury, Clément Delmas |
| Source: |
Frontiers in Cardiovascular Medicine, Vol 10 (2023) |
| Publisher Information: |
Frontiers Media S.A., 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: |
cardiogenic shock, supraventricular tachycardia, epidemiology, prognosis, mortality, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| More Details: |
BackgroundCardiogenic shock (CS) is the most severe form of heart failure (HF), resulting in high early and long-term mortality. Characteristics of CS secondary to supraventricular tachycardia (SVT) are poorly reported. Based on a large registry of unselected CS, we aimed to compare 1-year outcomes between SVT-triggered and non-SVT-triggered CS.MethodsFRENSHOCK is a French prospective registry including 772 CS patients from 49 centers. For each patient, the investigator could report 1–3 CS triggers from a pre-established list (ischemic, mechanical complications, ventricular/supraventricular arrhythmia, bradycardia, iatrogenesis, infection, non-compliance, and others). In this study, 1-year outcomes [rehospitalizations, mortality, heart transplantation (HTx), ventricular assist devices (VAD)] were analyzed and adjusted for independent predictive factors.ResultsAmong 769 CS patients included, 100 were SVT-triggered (13%), of which 65 had SVT as an exclusive trigger (8.5%). SVT-triggered CS patients exhibited a higher proportion of male individuals with a more frequent history of cardiomyopathy or chronic kidney disease and more profound CS (biventricular failure and multiorgan failure). At 1 year, there was no difference in all-cause mortality (43% vs. 45.3%, adjusted HR 0.9 (95% CI 0.59–1.39), p = 0.64), need for HTx or VAD [10% vs. 10%, aOR 0.88 (0.41–1.88), p = 0.74], or rehospitalizations [49.4% vs. 44.4%, aOR 1.24 (0.78–1.98), p = 0.36]. Patients with SVT as an exclusive trigger presented more 1-year rehospitalizations [52.8% vs. 43.3%, aOR 3.74 (1.05–10.5), p = 0.01].ConclusionSVT is a frequent trigger of CS alone or in association in more than 10% of miscellaneous CS cases. Although SVT-triggered CS patients were more comorbid with more pre-existing cardiomyopathies and HF incidences, they presented similar rates of mortality, HTx, and VAD at 1 year, arguing for a better overall prognosis.Clinical Trial Registrationhttps://clinicaltrials.gov, identifier: NCT02703038. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2297-055X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fcvm.2023.1167738/full; https://doaj.org/toc/2297-055X |
| DOI: |
10.3389/fcvm.2023.1167738 |
| Access URL: |
https://doaj.org/article/4e9cab32223c4b198c22e913199a91a7 |
| Accession Number: |
edsdoj.4e9cab32223c4b198c22e913199a91a7 |
| Database: |
Directory of Open Access Journals |
